0001209191-23-037984.txt : 20230616 0001209191-23-037984.hdr.sgml : 20230616 20230616170854 ACCESSION NUMBER: 0001209191-23-037984 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230614 FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simson Jake CENTRAL INDEX KEY: 0001863094 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40475 FILM NUMBER: 231022199 MAIL ADDRESS: STREET 1: C/O JANUX THERAPEUTICS, INC. STREET 2: 11099 N. TORREY PINES ROAD, SUITE 290 CITY: LA JOLLA STATE: CA ZIP: 92037 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Janux Therapeutics, Inc. CENTRAL INDEX KEY: 0001817713 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822289112 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 751-4493 MAIL ADDRESS: STREET 1: 10955 VISTA SORRENTO PARKWAY STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-14 0 0001817713 Janux Therapeutics, Inc. JANX 0001863094 Simson Jake C/O JANUX THERAPEUTICS, INC. 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130 1 0 0 0 0 Stock Option (right to buy) 13.22 2023-06-14 4 A 0 12500 0.00 A 2033-06-13 Common Stock 12500 12500 D The shares subject to the option will vest in equal monthly installments over the 12 months following June 14, 2023, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Company's stockholders. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Advisor"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The Reporting Person is obligated to turn over to the Advisor any net cash or stock received from the option, which will offset advisory fees owed by the Fund and the Nexus Fund II to the Advisor. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. /s/ Tighe Reardon, Attorney-in-Fact 2023-06-16